ERBB2 and non-small cell lung carcinoma: Limited clinical benefit observed in HER2 amplified NSCLC patients led to the conclusion that overexpression and amplification seem to be a suboptimal biomarker for patients’ stratification, shifting the attention to HER2 mutations as valuable targets.